Actively Recruiting

Phase 3
Age: 18Years +
All Genders
NCT05335252

Dronabinol After Arthroscopic Surgery

Led by Northwestern University · Updated on 2025-04-29

30

Participants Needed

1

Research Sites

257 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of the proposed study is to evaluate the efficacy of dronabinol for postoperative pain after arthroscopic surgery of the knee. The investigators hypothesize that dronabinol will relieve pain, reduce opioid consumption and will result in few negative side effects. If this pilot study shows promising results the investigators will expand the trial to include additional arthroscopic surgeries (hip, shoulder) and other types of orthopaedic surgery.

CONDITIONS

Official Title

Dronabinol After Arthroscopic Surgery

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Patient who will undergo arthroscopic surgery of the knee including meniscectomy
  • Patient who will undergo arthroscopic surgery of the knee including synovectomy
  • Patient who will undergo arthroscopic surgery of the knee including chondroplasty
  • Patient who will undergo arthroscopic surgery of the knee including loose body removal
Not Eligible

You will not qualify if you...

  • Patients under age 18 years
  • Patients who cannot provide consent
  • Patients who are pregnant, breastfeeding, or trying to become pregnant during the study
  • Patients with an allergy to any study drug
  • Patients who are lactose-intolerant
  • Patients undergoing revision surgery
  • Patients undergoing open surgery
  • Patients with comorbidities preventing surgery
  • Patients with a history of mania, depression, or schizophrenia
  • Patients taking anticholinergic agents
  • Patients taking benzodiazepines
  • Patients taking central nervous system depressants
  • Patients taking droperidol
  • Patients taking hydroxyzine
  • Patients taking levomepromazine or methotrimeprazine
  • Patients taking monoamine oxidase inhibitors
  • Patients taking ritonavir
  • Patients taking selective serotonin reuptake inhibitors
  • Patients taking sympathomimetics
  • Patients taking St. John's Wort
  • Patients with current diagnosed alcohol or drug abuse
  • Patients who cannot or will not follow medication restrictions
  • Patients who do not agree to abstain from marijuana, cannabidiol (CBD), alcohol, or other drugs during treatment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Northwestern University Feinberg School of Medicine

Chicago, Illinois, United States, 60611

Actively Recruiting

Loading map...

Research Team

M

Melissa J Shauver, MPH

CONTACT

A

Abbie P Bennett, MS

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here